Hormonal
In diet-induced obesity, brain glucose-sensing neurons (specifically in the arcuate nucleus and ventromedial hypothalamus) become hyporesponsive to glucose, leading to defective sympathetic regulation and contributing to metabolic efficiency and obesity development.
Obesity is not just a simple math problem of calories in vs. calories out; your brain's ability to sense glucose and regulate energy expenditure may be biologically impaired. This 'glucose sensing defect' makes your body more efficient at storing fat and resistant to weight loss. Understanding this biological resistance is key to addressing obesity, as it suggests that standard caloric restriction alone may be insufficient without addressing the underlying neural dysregulation.
In rats with diet-induced obesity and hyperinsulinemia, GR neurons are hyporesponsive to glucose... DIO rats also exhibit several other signs of reduced central glucose sensitivity... reduced central sensitivity to glucose may be a predisposing factor to the development of increased metabolic efficiency and obesity when obesity-prone rats are exposed to a high-energy diet.
Why this rating
The paper is an invited review summarizing rodent models; it cites specific studies but does not present new primary clinical data.
Source
Brain glucose sensing and body energy homeostasis: role in obesity and diabetes
Barry E. Levin et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · 1999
DOI 10.1152/ajpregu.1999.276.5.r1223
More from this paper
- Insulin-dependent diabetes (IDDM) and repeated hypoglycemia impair brain glucose sensing, leading to defective counterregulatory responses and hypoglycemia unawareness.Moderate
- Brain glucose-sensing neurons (GR and GS neurons) regulate energy homeostasis by modulating sympathetic and parasympathetic nervous system activity in response to glucose levels.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →